Menlo Therapeutics Expands its Management Team

REDWOOD CITY, Calif., Oct. 17, 2017 -- (Healthcare Sales & Marketing Network) -- Menlo Therapeutics Inc., a late stage biopharmaceutical company, is developing a neurokinin 1 (NK-1) receptor antagonist (serlopitant) for the treatment of pruritus (itch) as... Biopharmaceuticals, Dermatology, Personnel Menlo Therapeutics, serlopitant, pruritus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news